| Title |
Radium 223 dichloride for prostate cancer treatment
|
|---|---|
| Published in |
Drug Design, Development and Therapy, September 2017
|
| DOI | 10.2147/dddt.s122417 |
| Pubmed ID | |
| Authors |
Emmanuel Deshayes, Mathieu Roumiguie, Constance Thibault, Philippe Beuzeboc, Florent Cachin, Christophe Hennequin, Damien Huglo, François Rozet, Diana Kassab-Chahmi, Xavier Rebillard, Nadine Houédé |
| Abstract |
Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10 years. Among them, radium-223 dichloride (Xofigo(®)) is a radioactive isotope that induces irreversible DNA double-strand breaks and consequently tumor cell death. Radium-223 dichloride is a calcium-mimetic agent that specifically targets bone lesions. Radium-223 dichloride has been approved for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases, without known visceral metastases. In this review, first we summarize the interplay between prostate tumor cells and bone microenvironment; then, we discuss radium-223 dichloride mechanism of action and present the results of the available clinical trials and future developments for this new drug. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 128 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 128 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 25 | 20% |
| Student > Ph. D. Student | 18 | 14% |
| Student > Master | 13 | 10% |
| Other | 12 | 9% |
| Researcher | 9 | 7% |
| Other | 16 | 13% |
| Unknown | 35 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 20% |
| Pharmacology, Toxicology and Pharmaceutical Science | 14 | 11% |
| Biochemistry, Genetics and Molecular Biology | 11 | 9% |
| Chemistry | 10 | 8% |
| Nursing and Health Professions | 9 | 7% |
| Other | 20 | 16% |
| Unknown | 38 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 September 2023.
All research outputs
#7,994,598
of 25,461,852 outputs
Outputs from Drug Design, Development and Therapy
#543
of 2,272 outputs
Outputs of similar age
#116,082
of 324,678 outputs
Outputs of similar age from Drug Design, Development and Therapy
#14
of 47 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 2,272 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,678 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.